86639-52-3
Chemical Structure
SN-38
Synonym(s): 7-Ethyl-10-hydroxycamptothecin
- CAS No.: 86639-52-3
- Formula:C22H20N2O5
- Molecular Weight:392.40
IUPAC Name: (S)-4,11-diethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione
InChIKey: FJHBVJOVLFPMQE-QFIPXVFZSA-N
SMILES: O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C2)=O
Biological Activity: SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 can bind to RPL15. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254)[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SN-38 | 99.94% | SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 can bind to RPL15. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SN-38 (Standard) | 99.76% | SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SN-38-d3 | 98.79% | SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SN-38-13C6 | SN-38-13C6 (7-Ethyl-10-hydroxycamptothecin-13C6) is the 13C-labeled SN-38 (HY-13704). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 can bind to RPL15. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-W665464(Rac)-7-Ethyl-10-hydroxycamptothecin -
Similarity Score 0.88
HY-W7402217-Ethylcamptothecin-d3-1 -
Similarity Score 0.87
HY-N2108R7-Ethylcamptothecin (Standard) -
Similarity Score 0.86
HY-158230SN-398 -
Similarity Score 0.84
HY-125930T-2513 -
Similarity Score 0.83
HY-125930AT-2513 hydrochloride -
Similarity Score 0.81
HY-16427110-Boc-SN-38 -
Similarity Score 0.81
HY-1591627-(2-Aminoethyl)camptothecin -
Similarity Score 0.80
HY-W740426N-Desmethyl topotecan -
Explore the MedChemAI to find more analogs
References
- [1]. Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19(6):1493-8. [Content Brief]
- [2]. Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56. [Content Brief]
- [3]. Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187-4191. [Content Brief]
- [4]. Aaron T Jacobs, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022 Oct:204:115209. [Content Brief]
